Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Enzyme replacement therapy in Fabry's disease].

L Alvarez1, C del Pozo, M Trigueros

  • 1Secci6n de Nefrología, Hospital de Alcoy, Alicante.

Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia
|August 2, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Practices of low value or unnecessary practices in vascular prevention: Document of the Spanish Interdisciplinary Committee for Vascular Prevention.

Hipertension y riesgo vascular·2025
Same author

Exercise-induced anxiety impairs local and systemic inflammatory response and glucose metabolism in C57BL/6J mice.

Brain, behavior, & immunity - health·2024
Same author

Clinical and genetic factors involved in Porto-sinusoidal vascular disorder after oxaliplatin exposure.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2024
Same author

Influence of the typology and timing of childhood trauma in psychoticism.

Archives of women's mental health·2024
Same author

Capacitors Based on Polypyrrole Nanowire Electrodeposits.

Polymers·2022
Same author

Fatty liver index as a predictor for type 2 diabetes in subjects with normoglycemia in a nationwide cohort study.

Scientific reports·2021

Enzyme replacement therapy for Fabry disease improved kidney function in a patient with chronic renal failure. Treatment reduced disease manifestations and improved renal function after therapy cessation.

Area of Science:

  • Nephrology
  • Genetics
  • Metabolic Disorders

Background:

  • Fabry disease is a rare genetic disorder causing globotriaosylceramide accumulation.
  • Chronic renal failure is a common complication of Fabry disease.
  • Enzyme replacement therapy (ERT) aims to restore alpha-galactosidase A activity.

Observation:

  • A 56-year-old man with chronic renal failure was diagnosed with Fabry disease.
  • Diagnosis was confirmed by low alpha-galactosidase A activity and genetic mutation.
  • Percutaneous kidney biopsy revealed globotriaosylceramide deposits.

Findings:

  • The patient received enzyme replacement therapy with alpha-galactosidase A.
  • After 18 months of ERT, a repeat kidney biopsy showed persistent renal deposits.

Related Experiment Videos

  • Six months post-therapy, renal function improved, and classic Fabry disease symptoms resolved.

    • Implications:

    • ERT may stabilize or improve renal function in Fabry disease patients.
    • Long-term monitoring is crucial to assess treatment efficacy and disease progression.
    • This case highlights the potential benefits of ERT in managing Fabry nephropathy.